Compare Duke Energy Corp (DUK) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Moderna, Inc. — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while Moderna, Inc. trades at $225.15 (market cap $78.65B). The key difference: Duke Energy Corp is the larger of the two by market cap, and Duke Energy Corp pays a 3.71% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Moderna, Inc. for 59 Days on average.
| DUK | MRNA | |
|---|---|---|
Market Cap | $91.10B | $78.65B |
Volume | 4,199,050 | 37,373,437 |
Sector | Utilities | Health |
52-Week High | $133.46 | $203.46 |
52-Week Low | $113.23 | $22.36 |
Typical Hold Time | 74 Days | 59 Days |
Enterprise Value | $183.61B | $74.80B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.55, up 0.91% today, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue grew to $32.24B in 2025, and net income margin improved to 15.78%. Recent news highlights dividend declarations and data center growth opportunities, though rising Treasury yields pose a headwind for utility stocks.
DUK offers a stable dividend and benefits from data center demand, but high debt levels and interest rate sensitivity present risks. Analyst consensus is a Buy with a $134.44 price target, implying 15% upside. The stock's valuation is reasonable with a P/E of 17.6, supporting a cautious bullish outlook amid macroeconomic pressures.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
